Having already spoken to Generics Bulletin about the early days of his now decade-long tenure as director general of European off-patent industry association Medicines for Europe – in the first part of an exclusive three-part interview (see sidebar) – Adrian van den Hoven subsequently turned to reflect on the various successes and challenges that he and the organization have encountered over the past ten years.
Triumphs And Crises: European Industry Chief Reflects On The Past Ten Years
Medicines For Europe Director General Adrian Van Den Hoven Highlights Achievements
In the second part of a three-part interview with Generics Bulletin, Medicines for Europe director general Adrian van den Hoven discusses the rise in prominence of biosimilars in Europe, reflects on off-patent industry efforts to deal with crises such as the COVID-19 pandemic and the war in Ukraine, and highlights achievements such as the SPC manufacturing waiver.
